Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastric02: A Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan in Western Patients With HER2+ Unresectable/Metastatic Gastric/Gastroesophageal Junction Cancer Who Progressed on or After Trastuzumab-Containing Regimen | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastric02: A Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan in Western Patients With HER2+ Unresectable/Metastatic Gastric/Gastroesophageal Junction Cancer Who Progressed on or After Trastuzumab-Containing Regimen

By ESMO 2022 Conference Coverage FEATURING Geoffrey Ku

By ESMO 2022 Conference Coverage FEATURING Geoffrey Ku

12 views

September 27, 2022

Comments 0

Login to view comments. Click here to Login